Biotechnology Press Releases

A new techno-thriller reimagines vampire lore as an ancient biological system—blending speculative science, hidden history, and modern suspense.

The new Public Benefit Corporation establishes a dedicated philanthropic arm for the deep tech innovator, cementing its commitment to funding community health, education, and welfare initiatives in the American interior.

​The capital accelerates stealth LNP delivery for gene therapies, driven by an unprecedented 100% LLM free neurosymbolic AI that dramatically outperforms commercial tech giants in rigorous scientific reasoning and consciousness diagnostics.

Xycota Biosciences, LLC ("Xycota"), an early-stage biotechnology company focused on brain repair therapeutics, today announced the formal unveiling of its neuro-restoration platform, anchored by newly published mechanistic evidence in the Nature...

Offering affordable V1.0 and V2.0 internships, workshops, and license courses in bioinformatics, ensuring global student access for under ₹100.

CEO Jordan Bekemeier and Metavalis partner with candidate Trent Davis to distribute winter essentials.

o2h Discovery, a preclinical contract research organization (CRO) with a fully integrated, multi-modality drug discovery platform, is pleased to announce the launch of the latest edition of the o2h Kickstarter in "North America." This program is...

The veteran led deep tech firm taps the renowned regulatory strategist and PharmaVoice 100 Honoree to architect the compliance framework for its re-dosable genetic medicines and solid state neural preservation systems.

The veteran led deep tech firm defines a new standard for optical computing, initiating the development of a proprietary differentiable physics kernel to solve the Non Linear Schrödinger Equation.

Missouri Based Biotech Firm Reveals "Project AETHELGAARD"A Unified Physics Architecture capable of 1 Tbps Neural State Transfer and Geological Scale Data Preservation.

Elite Advisory Board Comprising Veterans from Moderna, NIH, and U.S. Defense Assembled to Guide Secure LNP Development in the Ozarks.

Data driven signal validates the company's "Failure Doctrine" operational model, positioning the Missouri based firm as a pre-seed outlier in the convergence of genomic medicine and optical computing.

Bioengineering firm recruiting founding advisors in Lipid Physics, Hepatology, and Regulatory Affairs to guide its Smart LNP 3.0 platform and Dec 24th IP filing.

Next Move Strategy Consulting reports that the global Infectious Disease Diagnostics Market is projected to reach around USD 35 billion by 2030, expanding at a CAGR of approximately 10% from 2024 to 2030.

The global AI in biotechnology market was valued at USD 3.23 billion in 2024, and is expected to reach USD 14.97 billion by 2033, rising at a CAGR of 21.1% during the forecast period.

Collaborative research between Manhattan BioSolutions and the Institute of Chemical Biology & Drug Discovery (ICB&DD) at Stony Brook University will advance next-generation ADC platform using novel TxD payloads

NEXS Technology Group is excited to announce its acceptance into the prestigious AWS Startup Program, a significant milestone that will propel the development and deployment of CancerScope-AI, our state-of-the-art artificial intelligence tool.

NEXS BioMedica, a forward-thinking biotech pharmaceutical company, proudly introduces CancerScope-AI, an innovative artificial intelligence system set to transform the battle against rare cancers.

Manhattan BioSolutions, Inc. ("MABS"), an emerging biotechnology company developing new classes of precision biologics that harness natural host defense mechanisms, today announced that its RNA-targeting therapeutic, MABS-139, will be evaluated in...